The needs of the caregiver in the long-term treatment of Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 18, Issue SUPPL. 1, 2004, Pages

  Bullock, Roger ^a  

^a VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Alzheimer disease; Behavioral symptoms; Caregiver time; Galantamine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE;

ALZHEIMER DISEASE; CAREGIVER; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DISEASE COURSE; EMOTIONAL STRESS; FAMILY; HEALTH CARE NEED; HOME CARE; HUMAN; MENTAL STRESS; NURSING HOME; PATIENT CARE; PHYSICAL STRESS; PRIORITY JOURNAL; RELATIVE; SOCIOECONOMICS;

AGED; ALZHEIMER DISEASE; CAREGIVERS; CHOLINESTERASE INHIBITORS; COST OF ILLNESS; DISEASE PROGRESSION; GALANTAMINE; HUMANS; LONG-TERM CARE; MENTAL DISORDERS; NOOTROPIC AGENTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 2942535826     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000127493.65032.9a     Document Type: Conference Paper

References (62)

1. Gauthier S, Gelinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr. 1997;9(suppl 1):163-165.
2. Borson S, Scanlan J, Brush M, et al. The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15:1021-1027.
3. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708-714.
4. Gauthier S. Managing expectations in the long-term treatment of Alzheimer's disease. Gerontology. 1999;45(suppl 1):33-38.
5. Alzheimer's Association. Who Cares? Families Caring for Persons with Alzheimer's Disease. Alzheimer's Association & National Alliance for Caregiving (NAC), 1999:1-37.
6. Stone R, Cafferata GL, Sangl J. Caregivers of the frail elderly: a national profile. Gerontologist. 1987;27:616-626.
7. Beach DL. Family caregiving: the positive impact on adolescent relationships. Gerontologist. 1997;37:233-238.
8. Hux MJ, O'Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and costs of caring. CMAJ. 1998;159:457-465.
9. Whitehouse PJ, Winblad B, Shostak D, et al. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary. Alzheimer Dis Assoc Disord. 1998;12:266-280.
10. Volicer L, Hurley A. Hospice Care for Patients With Advanced Progressive Dementia. New York, NY: Springer; 1998:xii.
11. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull. 1988;24:653-655.
12. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48(suppl):9-15.
13. Teri L. Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. Alzheimer Dis Assoc Disord. 1997;11(suppl 4):S35-S38.
14. George LK, Gwyther LP. Caregiver well-being: a multidimensional examination of family caregivers of demented adults. Gerontologist. 1986;26:253-259.
15. Hu TW, Huang LF, Cartwright WS. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist. 1986;26:158-163.
16. Moss MS, Lawton MP, Kleban MH, et al. Time use of caregivers of impaired elders before and after institutionalization. J Gerontol. 1993;48: S102-S111.
17. Max W, Webber P, Fox P. Alzheimer's disease. The unpaid burden of caring. J Aging Health. 1995;7:179-199.
18. Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med. 2001;16:770-778.
19. Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther. 1995;58:228-236.
20. Cantor M. Caring for the frail elderly: impact on family, friends, and neighbors [abstract]. Presented at the Meeting of the Gerontological Society of America, 1980: San Diego, CA.
21. Dunkin JJ, Anderson-Hanley C. Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention. Neurology. 1998;51:S53-S60.
22. Office of Technology Assessment. Losing a million minds: confronting the tragedy of Alzheimer's disease and other dementias. Washington, DC: US Government Printing Office; 1987.
23. Teri L, Truax P. Assessment of depression in dementia patients: association of caregiver mood with depression ratings. Gerontologist. 1994;34:231-234.
24. Burns A. The burden of Alzheimer's disease. Int J Neuropsychopharmacol. 2000;3:31-38.
25. Goldberg DP. Manual for the General Health Questionnaire. Windsor, UK: NFER-Nelson Publishing Company: 1978.
26. Burvill PW, Knuiman MW. Which version of the General Health Questionnaire should be used in community studies? Aust N Z J Psychiatry. 1983;17:237-242.
27. Gonzalez-Salvador MT, Arango C, Lyketsos CG, et al. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry. 1999;14:701-710.
28. Katon W. Depression: somatic symptoms and medical disorders in primary care. Compr Psychiatry. 1982;23:274-287.
29. Baumgarten M, Battista RN, Infante-Rivard C, et al. The psychological and physical health of family members caring for an elderly person with dementia. J Clin Epidemiol. 1992;45:61-70.
30. Hooker K, Monahan D, Shifren K, et al. Mental and physical health of spouse caregivers: the role of personality. Psychol Aging. 1992;7:367-375.
31. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84:1261-1264.
32. Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer's disease. Int J Geriatr Psychiatry. 1998;13:248-256.
33. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff. 1993;12:164-176.
34. Stommel M, Collins CE, Given BA. The costs of family contributions to the care of persons with dementia. Gerontologist. 1994;34:199-205.
35. Fillit HM. The pharmacoeconomics of Alzheimer's disease. Am J Manag Care. 2000;6:S1139-S1144.
36. Huppert FA, Roth M, Gore M. Psychological factors. Health and Lifestyle Survey: preliminary report of a nationwide survey of physical and mental health, attitudes and lifestyle of a random sample of 9003 British adults. London, UK: Health Promotion Research Trust; 1987.
37. Getsios D, Caro JJ, Caro G, et al. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology. 2001;57:972-978.
38. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
39. Opit L, Pahl J. Institutional care for elderly people: can we predict admissions? Research, Policy and Planning. 1993;10:2-5.
40. Kavanagh S, Knapp M. Cognitive disability and direct care costs for elderly people. Br J Psychiatry. 1999;174:539-546.
41. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology. 1996;47:166-177.
42. Kaufer D. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord. 1998;9(suppl 2):8-14.
43. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210-215.
44. Pettenati C, Donato MF. Behavioral symptoms of Alzheimer's disease: improvement by donepezil. Neurobiol Aging. 1998;19(suppl 4):S182.
45. Kaufer DI, Catt K, Pollock BG, et al. Donepezil in Alzheimer's disease: relative cognitive and neuropsychiatric responses and impact on caregiver distress [abstract]. Neurology. 1998;50:A89.
46. Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990;147:1049-1051.
47. Wimo A, Gustafsson L, Mattson B. Predictive validity of factors influencing the institutionalization of elderly people with psycho-geriatric disorders. Scand J Prim Health Care. 1992;10:185-191.
48. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157:4-15.
49. Mastey V. Donepezil reduces the time caregivers spend providing care: results of a one-year, double-blind, randomized trial in patients with mild-to-moderate Alzheimer's disease. Poster presented at 14th Annual Meeting of the American Association of Geriatric Psychiatry: San Francisco, CA.
50. Fillit HM, Gutterman EM, Brooks RL. Impact of donepezil on caregiving burden for patients with Alzheimer's disease. Int Psychogeriatr. 2000;12:389-401.
51. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-2268.
52. Tariot P, Kershaw P, Yuan W. Galantamine postpones the emergence of behavioral symptoms in Alzheimer's Disease: a 5-month, randomized, placebo-controlled study. Poster presented at World Alzheimer's Congress, July 9-13, 2000: Washington, DC.
53. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276.
54. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ. 2000;321:1445-1449.
55. Blesa R. Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord. 2000;11(suppl 1):28-34.
56. Lilienfeld S, Gaens E. Galantamine alleviates caregiver burden in Alzheimer's disease: a 12-month study. Poster presented at 5th Congress of the European Federation of Neurological Societies, October 14-18, 2000: Copenhagen, Denmark.
57. Sano M, Wilcock GK, Van Baelen B, et al. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry. 2003;18:942-950.
58. Meletiche DM, Bolge S, Small GW. Galantamine reduces caregiver time: an analysis of a national sample of Alzheimer's patients living in the community. Poster presented at 8th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-21, 2003: Arlington, VA.
59. The Alzheimer's disease caregiver project. final report-wave 10. Princeton. NJ: Consumer Health Sciences. 2001;0:1-99.
60. Weiner M, Powe NR, Weller WE, et al. Alzheimer's disease under managed care: implications from Medicare utilization and expenditure patterns. J Am Geriatr Soc. 1998;46:762-770.
61. Gutterman EM, Markowitz JS, Lewis B, et al. Cost of Alzheimer's disease and related dementia in managed-medicare. J Am Geriatr Soc. 1999;47:1065-1071.
62. Annerstedt L, Elmstahl S, Ingvad B, et al. Family caregiving in dementia-an analysis of the caregiver's burden and the " breaking-point" when home care becomes inadequate. Scand J Public Health. 2000;28:23-31.